Results 71 to 80 of about 1,844 (180)
Mavacamten for hypertrophic obstructive cardiomyopathy [PDF]
The Lancet, 2021 Eduard, Quintana +2 more
openaire +2 more sources
The Journal of Physiology, Volume 603, Issue 19, Page 5369-5385, October 1, 2025.Abstract figure legend Rapidly stretched cardiac trabeculae exhibit a viscoelastic tension response characterized by a power‐law decay. Increasing calcium concentration substantially increases the tension peak severalfold, even when active myosin contraction is eliminated.
Filip Ježek +3 more
wiley +1 more source
Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy [PDF]
Hypertrophic obstructive cardiomyopathy (HCM) is the most common heterogeneous genetic cardiovascular disorder. Its pathophysiology involves left ventricular hypertrophy, increased fibrosis, hypercontractility, and reduced compliance.
Bansal, Alka +5 more
core +2 more sources
CPT: Pharmacometrics & Systems PharmacologyMavacamten is a cardiac myosin inhibitor for adults with obstructive hypertrophic cardiomyopathy (HCM). Dose optimization is performed 4 weeks after starting mavacamten, guided by periodic echo measurements of Valsalva left ventricular outflow tract ...
Xiaojie Wu +8 more
doaj +1 more source
Mavacamten in Right Ventricular Outflow Tract Obstruction
JACC: Case ReportsRight ventricular outflow tract (RVOT) obstruction is a rare complication of ventricular hypertrophy in patients with hypertrophic cardiomyopathy (HCM). This study presents an unusual case of a patient with HCM with severe RVOT obstruction that was relieved successfully through the use of mavacamten.
Jasmine K. Malhi +6 more
openaire +3 more sources
Muscle &Nerve, Volume 72, Issue 3, Page 399-407, September 2025.ABSTRACT Introduction/Aims Sevasemten (EDG‐5506) is an orally administered, investigational small molecule that selectively modulates fast muscle fiber contraction by inhibiting fast myosin ATPase. This study assessed the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) of sevasemten in healthy adult volunteers (HVs) and adults ...
Joanne Donovan +11 more
wiley +1 more source
Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
Drug Design, Development and Therapy, 2023 Tiffany Dong,* Ben Alencherry,* Susan Ospina, Milind Y Desai Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA*These authors contributed equally to this workCorrespondence: Milind ...
Dong T, Alencherry B, Ospina S, Desai MY
doaj
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy [PDF]
, 2023 Olivotto, Iacopo
core +1 more source
Pharmacogenomics in the UK National Health Service: Progress towards implementation
British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2241-2250, August 2025.Over the past decade there has been considerable and growing enthusiasm about the promise of using genomics to inform healthcare. In particular, using genetic data to inform prescribing practice has emerged as a compelling policy priority for health systems around the world, not least in the NHS.
John H. McDermott +3 more
wiley +1 more source
PLoS ONEBackgroundHypertrophic Cardiomyopathy (HCM) is a complex cardiac condition characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left ventricular outlet tract (LVOT).
Rahul Vyas +8 more
doaj +1 more source